Einhorn S, Strander H
Adv Exp Med Biol. 1978;110:159-74. doi: 10.1007/978-1-4615-9080-4_13.
With the object of examining the anti-tumour effect of exogenous interferon therapy in man a research programme has been initiated at the Karolinska Hospital. Established cell lines obtained from patients with Burkitt's and other types of lymphoma, leukaemia, osteosarcoma, mammary carcinoma and fibrosarcoma and from fibroblast cultures displayed a variable sensitivity to the cell multiplication inhibitory activity of interferon. All the monolayer cultures tested were found to be sensitive to interferon at concentrations between 10 and 300 units/ml. Some lymphoma cell lines were not sensitive to interferon even at concentrations as high as 10.000 units/ml, while others were sensitive at concentrations between 2 and 300 units/ml. The interferons tested appeared to show a degree of tissue specificity. Controlled studies in vivo are being performed on osteosarcoma, juvenile papilloma of the larynx, multiple myeloma and small-cell carcinoma of the lung. The clinical results of this research obtained to date, together with the results obtained in model experiments, would appear to warrant accelerated production of human interferon.
为了研究外源性干扰素疗法对人体的抗肿瘤作用，卡罗琳斯卡医院启动了一项研究计划。从患有伯基特淋巴瘤和其他类型淋巴瘤、白血病、骨肉瘤、乳腺癌和纤维肉瘤的患者以及成纤维细胞培养物中获得的已建立细胞系，对干扰素的细胞增殖抑制活性表现出不同的敏感性。所有测试的单层培养物在10至300单位/毫升的浓度下对干扰素敏感。一些淋巴瘤细胞系即使在高达10000单位/毫升的浓度下也对干扰素不敏感，而其他细胞系在2至300单位/毫升的浓度下敏感。所测试的干扰素似乎表现出一定程度的组织特异性。正在对骨肉瘤、喉幼年乳头状瘤、多发性骨髓瘤和肺小细胞癌进行体内对照研究。迄今为止这项研究的临床结果，连同在模型实验中获得的结果，似乎有理由加快人类干扰素的生产。
